Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Net Income: 2023-2025

Historic Net Income for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's Net Income fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 50.07%. This contributed to the annual value of -$161.3 million for FY2024, which is 334.62% down from last year.
  • Zenas BioPharma's Net Income amounted to -$51.5 million in Q3 2025, which was up 1.39% from -$52.2 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Net Income high stood at $35.6 million for Q3 2023, and its period low was -$56.5 million during Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median Net Income value was -$38.0 million (recorded in 2024), while the average stood at -$31.9 million.
  • Data for Zenas BioPharma's Net Income shows a maximum YoY crashed of 208.37% (in 2024) over the last 5 years.
  • Zenas BioPharma's Net Income (Quarterly) stood at -$24.8 million in 2023, then slumped by 128.15% to -$56.5 million in 2024, then crashed by 33.40% to -$51.5 million in 2025.
  • Its Net Income was -$51.5 million in Q3 2025, compared to -$52.2 million in Q2 2025 and -$33.6 million in Q1 2025.